Big Endothelin-1

Mechanism of Action

• Cleaved by membrane-bound ECE-1 at the Trp21-Val22 bond to generate active ET-1 (aa1-21) and a C-terminal fragment (aa22-38)
• Some vasoconstrictor activity retained via weak ETA receptor binding (~1% of ET-1 potency)
• Alternative cleavage by chymase (mast cell serine protease) generates ET-1(1-31), a biologically active variant
• Circulating Big ET-1 serves as a stable surrogate marker for ET-1 production (ET-1 half-life is too short to measure reliably)
• Cardiac myocytes and fibroblasts can convert Big ET-1 locally via ECE-1 during hypertrophy and failure

Research Findings

• Plasma Big ET-1 levels strongly predict cardiovascular outcomes in heart failure, acute coronary syndrome, and post-MI patients
• Big ET-1 > 0.27 pmol/L in heart failure associated with significantly elevated mortality risk in prospective studies
• Big ET-1 is more stable than ET-1 in plasma (15-20 min vs 4-7 min half-life), making it the preferred clinical biomarker
• ECE-1 inhibitors reduce Big ET-1 to ET-1 conversion and are being investigated for heart failure and pulmonary hypertension
• Serum Big ET-1 correlates with pulmonary artery pressures in PAH patients and tracks response to bosentan therapy

Research Protocols

• Biomarker measurement: plasma Big ET-1 by immunoassay (reference range < 0.1-0.27 pmol/L depending on assay)
• Pharmacological challenge: Big ET-1 IV infusion to assess ECE-1 activity in vivo (research only)
• Not used as a therapeutic agent; monitored as cardiovascular biomarker
• ECE-1 inhibitor studies: measure Big ET-1 accumulation to confirm ECE-1 blockade

Interactions

• ECE-1: primary activating enzyme; ECE-1 inhibitors block Big ET-1 to ET-1 conversion
• Chymase: alternative processing to ET-1(1-31); relevant in cardiac tissue
• Bosentan/ambrisentan: do not directly affect Big ET-1; block downstream ET-1 receptor signaling

Safety Profile

Endogenous precursor. Elevated plasma Big ET-1 is a risk marker, not a causal agent itself. Not administered therapeutically. ECE-1 inhibitors targeting this pathway are in clinical development.

Legal & Regulatory

Biomarker; not approved as therapeutic